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Disease Monitoring by the Tumour Markers Cyfra 
21.1 and TPA in Patients with Non-small Cell Lung 
Cancer 
A. van der Gaast, T.C. Kok, G.S. Kho, B.G. Blijenberg and T.A.W. Splinter 
We evaluated the use of two tumour markers Cyfra 21.1 and tissue polypeptide antigen (TPA) for disease 
monitoring. Assessment of response to WHO criteria was compared to response assessment according to changes 
in the tumour marker levels. The criteria defined for marker response were a 65% decrease for a partial response 
and a 40% increase for progressive disease. When response evaluations with a positive lead time were included, 
72% of 115 evaluations for Cyfra 21.1 and 59% of 107 evaluations for TPA yielded the same result. Most discordant 
evaluations were caused by those evaluations whereby the patient achieved a partial response according to the 
WHO criteria and had normalisation of the marker. Less cases with a positive lead time, more negative lead 
times, and more patients with progressive disease without an increase of the marker were seen with TPA 
compared to Cyfra 21.1. In conclusion, Cyfra 21.1 follows the changes in the turnout load better than TPA. Rising 
levels of both markers nearly always indicate disease progression, and such knowledge easily obtained may 
prevent the continuation of ineffective treatment. 
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INTRODUCTION 
MANY PATIENTS with non-small cell lung cancer (NSCLC) 
present with advanced isease or will relapse after initial surgery 
and/or radiotherapy, and may become candidates for systemic 
treatment. The impact of chemotherapy on survival is, however, 
small and the benefit seems to be restricted to those patients who 
achieve an objective response to treatment [I]. Therefore, 
monitoring of treatment and early detection of those patients who 
progress during treatment is important to avoid continuation of 
unnecessary toxic treatment. 
The evaluation of response to chemotherapy may sometimes 
be difficult, especially in those cases where the bulk of disease is 
represented by non-evaluable lesions, and may require expensive 
and time-consuming investigations, such as computed tomogra- 
phy and magnetic resonance imaging. 
In a recent study, we reported our first results with the tumour 
marker, Cyfra 2 1.1, the antibody to which detects a fragment of 
cytokeratin 19 in serum [2]. We showed that the sensitivity to 
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Cyfra 21.1 in 212 patients with NSCLC, predominantly stage 
3a-b and 4, was 40%. In addition, the sensitivity to another 
cytokeratin marker, tissue polypeptide antigen (TPA), tested in 
the same group of patients was also 40%. The sensitivities for 
both markers were higher in patients with stage 4 disease than 
in patients with stage 3 disease. Median levels of Cyfra 2 1.1 were 
significantly higher in patients with squamous cell carcinomas 
compared with the median levels found in patients with adeno- 
carcinomas or large cell undifferentiated carcinomas. Further- 
more, we demonstrated that Cyfra 21.1 was a useful marker 
for monitoring chemotherapy in patients with squamous cell 
carcinoma. 
In the present study, we extended the monitoring data to 
include patients with adenocarcinoma and large cell undifferen- 
tiated carcinoma of the lung, and compared these results with 
those obtained with TPA. The TPA assay detects cytokeratins 
8,18 and 19 [3]. We have previously reported a high intermarker 
correlation between Cyfra 21.1 and TPA at diagnosis [2], and so 
investigated which one of these two markers would be the more 
accurate for disease monitoring. 
Patients 
PATIENTS AND METHODS 
The initial cohort included 212 patients with histologically 
proven inoperable NSCLC, from whom serum samples were 
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collected at diagnosis and during treatment for those who 
received chemotherapy. Fro.m this group of patients, 50 fulfilled 
the following eligibility criteria: (1) treated with chemotherapy; 
(2) a sufficient number of marker determinations during chemo- 
therapy i.e. at least three se:rum samples; (3) evaluable lesions; 
and (4) an elevated level of Cyfra 2 1.1 or TPA at the start of 
treatment. 
All patients were staged according to the guidelines of the 
American Joint Committee on Cancer [4]. Nodal status was 
confirmed histologically or cytologically by mediastinoscopy, 
mediastinotomy or thoracotomy for those patients with stage 
IIIa disease. Response to chemotherapy was assessed, ingeneral, 
after every two courses, according to standard WHO criteria [5] 
without knowledge of any tumour marker level. The following 
response criteria for tumour markers were used: complete 
response, normalisation of an elevated marker for at least 1 
month; partial response, decrease of 65% or more of an elevated 
marker for at least 1 month; stable disease, less than 65% 
decrease or less than 40% increase of an elevated marker; 
progressive disease, more than 40% increase of an elevated 
marker level or a rise from below to above the cut-off level. 
These criteria are based on the assumption that the tumour 
marker levels correspond to three-dimensional measurements of
the total body tumour load. A 50% decrease of a bidimensional 
measurement (WHO criteria) roughly corresponds to a 65% 
decrease of a volumetric measurement, and a 25% increase of a 
bidimensional measurement corresponds to a 40% increase of a 
volumetric measurement. When both methods of evaluation 
yielded the same result at ,the same time, the evaluation was 
called concordant. 
Marker assessments 
Serum Cyfra 2 1.1 assay vallues were determined using a solid- 
phase double determinant immunoradiometric assay (Centocor 
Diagnostics, Malvern, Pennsylvania, U.S.A.). This assay util- 
ises two monoclonal antibodies (KS 19.1 and BM 19.21) reactive 
with different epitopes expressed by cytokeratin 19 fragments. 
KS 19.1 is coated on the solid phase and the BM 19.21 antibody, 
radiolabelled with iodine 12 5, is used as a tracer. For the Cyfra 
2 1.1 assay, the coefficients for interassay variation were between 
7.0 and 11.9%. TPA was measured with a commercial kit 
(Protigen RIA Sangtec Medical Co, Bromma, Sweden) accord- 
ing to the manufacturer’s instructions. 
Cut-off values used in this study were 3.3 ng/rnl for Cyfra 
21.1 and 170 U/l for TPA. These cut-off values correspond to a 
%% specificity for both markers determined in 546 patients with 
non-malignant lung diseases [6]. 
RlESULTS 
The patient characteristics of the 50 eligible patients are listed 
in Table 1.37 of the 50 patie:nts had elevated levels of both Cyfra 
21.1 andTPA. 
A scattergram of the pretreatment levels of both markers is 
shown in Figure 1, demonstrating the high correlation between 
the two markersinpretreatment samples (r = 0.81,P < 0.001). 
Disease monitoring with Cyfi~! 2 1.1 
Of the 46 patients with an (elevated Cyfra 2 1 . 1 , 115 evaluations 
for response were performed. The concordance between the 
results of the clinical evaluations according to WHO criteria and 
the changes in the marker iaccording to the earlier mentioned 
criteria was 63%. 
Twenty-four of the 42 discordant evaluations were caused by 
Table 1. Patient characteristics 
Characteristic 
Number of 
patients (%) 
(n = 50) 
No. patients with both markers elevated 
No. patients with elevated TPA 
No. patients with elevated Cyfra 21.1 
Gender 
Female 
Male 
Median age (years) 58 
Range 39-71 
Performance (WHO) 
0 12 (24%) 
32 (64%) 
6 (12%) ‘ 
Stage 
IIIa 
IIIb 
IV 
Histology 
Adenocarcinoma 
Squamous cell carcinoma 
Large cell undifferentiated 
37 
41 
46 
10 (20%) 
40 (80%) 
13 (26%) 
11 (22%) 
26 (52%) 
12 (24%) 
29 (58%) 
9 (18%) 
r = 0.81 
P < 0.001 0 
Figure 1. Scattergram of Cyfra 21.1 versus TPA. 
patients with a clinical partial response and a decrease of 
the marker below the cut-off level (Table 2). Ten discordant 
evaluations could be explained by a positive lead time of the 
marker, i.e. the change in the tumour marker preceded the 
results obtained by the clinical evaluation by l-2 months. On 9 
of these 10 occasions, the marker indicated disease progression 
while the clinical response was stable disease; the tenth event 
occurred in a patient who had normalisation of the marker and 
stable disease, which later changed into a partial response. A 
negative lead time was observed once in a patient with progress- 
ive disease, while the tumour marker met the criteria for 
progressive disease only 4 weeks later. Five evaluations yielded 
stable disease clinically and a partial response according to the 
marker level on one occasion and a complete response indicated 
by the marker on four occasions. In most of these, tumour 
regression was observed, but was not sufficient to reach the 
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Table 2. Sununay of discordant elevations of Cyfra 2 1.1 
Total number of elevations 
Number of discordant evaluations 
Positive lead time 
Negative lead time 
Partial response according to WHO/complete response 
marker 
115 
42 
10 
1 
24 
Stable disease according to WHO/partial or complete 
response marker 
Stable disease according to WHO/progressive disease marker 
Progressive disease according to WHO/stable disease marker 
(marker increase l ss than 40%) 
5 
1 
1 
criteria for partial response. One patient had an increase in the 
marker level when clinical progression was documented, but 
this was not enough to meet the criteria set for marker pro- 
gression. The last discordant evaluation was in a patient who 
had progressive disease according to the marker, but stable 
disease according to the WHO criteria. This patient was sub- 
sequently treated with radiotherapy so that the possibility of a 
positive lead time of the marker could not be assessed. A 
summary of the discordant evaluations of Cyfra 21.1 is given in 
Table 2. 
Disease monitoring with TPA 
Of 41 patients with an elevated TPA, 107 evaluations for 
response were performed. The concordance between the results 
of the clinical evaluations according to WHO criteria and the 
changes in the marker was 54%. 
Five of the 49 discordant evaluations were due to a positive 
lead time of the marker, whereby the marker indicated disease 
progression while the clinical response was stable disease (Table 
3). A negative lead time was seen four times in patients with 
clinical progressive disease and progressive disease according to 
the tumour marker criteria l-2 months later. In 5 patients with 
disease progression according to the WHO criteria, the marker 
levels remained stable. A reduction in the TPA levels below the 
cut-off level was seen on 23 occasions when the clinical response 
was a partial response and on 11 occasions when the clinical 
response was stable disease. In one patient with a partial 
response, the marker level indicated stable disease. A summary 
of the discordant evaluations of TPA is given in Table 3. 
In Figure 2, an example is shown of Cyfra 21.1 and TPA 
levels during treatment, whereby the course of both markers is 
identical. An example of a patient with progressive disease and 
increasing Cyfra 2 1.1 levels, but a stable level of TPA is shown 
in Figure 3. 
Table 3. Summay of discordant evaluations of TPA 
Total number of evaluations 
Number of discordant evaluations 
Positive lead time 
Negative lead time 
Partial response according to WHO/complete response 
marker 
107 
49 
5 
4 
23 
Stable disease according to WHO/partial or complete 
response marker 
Progressive disease according to WHO/stable disease 
marker 
11 
5 
Partial response according to WHO/stable disease marker 1 
14 700 
PR = Partial response 
12 - PD = Progressive disease ,i 600 
I I I 
100 150 200 2500 
Days 
Figure 2. Course of Cyfra 21.1 and TPA during chemotherapy in a 
patient with a stage 4 adenocarcinoma of the lung. 
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3. Course of Cyfra 21.1 and TPA during chemotherapy in a . _ __ . __ _ 
patient with a stage 4 squamous cell carcinoma of the lung. 
DISCUSSION 
The most common application of serum tumour markers is 
disease monitoring, and tumour markers such as alpha-fetopro- 
tein, S-chorionic gonadotropin, prostate specific antigen, CA- 
15.3 and C-125 have become invaluable in the management of 
patients with testicular, prostate, breast and ovarian cancer [7]. 
The aim of the present study was to investigate whether Cyfra 
2 1.1 and TPA are useful serum tumour markers for disease 
monitoring in patients with NSCLC during chemotherapy. 
Although a number of studies have investigated the role of 
TPA for disease monitoring in NSCLC patients, in virtually 
none have criteria been defmed for marker response nor been 
correlated with response assessments according to standard 
WHO criteria. Monitoring data for Cyfra 21.1 are scarce. Since 
both markers measure cytokeratins, cytokeratin 19 for Cyfra 
21.1 and cytokeratin 8, 18 and 19 for TPA, we were also 
interested in a comparison between these two markers. More- 
over, it has also been claimed that the serum levels of TPA are 
indicative of the proliferation activity of a tumour [8]. 
Using strictly defined criteria for a marker response (i.e. a 
46% increase of the marker level for disease progression and a 
65% decrease in the marker level for a partial response) and 
considering evaluations with a positive lead time as concordant, 
we found a concordance between response valuation according 
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to standard WHO criteria and response valuation according to markers during chemotherapy nearly always indicate disease 
the marker criteria of 72% and 59% for Cyfra 2 1.1 and TPA, progression, and such information may prevent he continuation 
respectively. A substantial number of discordant evaluations for of ineffective treatment. The precise relationship between TPA 
both markers were caused by those evaluations whereby the and proliferation and the therapeutic implications, if any, 
patient achieved only a partial response according to the WHO remains unclear. 
criteria and had a decrease of the marker level below the cut-off 
level. Although such evaluations are discordant, they usually do 
not influence the treatment strategy for these patients. 
The differences between the two markers were that a positive 
lead time, whereby the marker indicated disease progression 
earlier than the evaluation according to the WHO criteria, was 
observed on nine occasions for Cyfra 2 1.1 and on five occasions 
for TPA. Furthermore, on nine occasions in patients with 
progressive disease, TPA levels increased only marginally or 
remained stable or met the criteria for marker response 1 month 
later. A third difference between TPA and Cyfra 2 1.1 was that 
more patients with stable disease had normalisation of the TPA 
levels compared with Cyfra 21.1. It thus seems that in some 
patients with progressive disease TPA is less well correlated with 
increase in tumour load than Cyfra 2 1.1, and further that more 
patients with stable disease have decreasing levels of TPA below 
the cut-off level than is observed with Cyfra 21.1. Whether these 
two observations are due to the fact that TPA levels may be 
correlated with the proliferation rate of the tumour rather than 
the total tumour load remains obscure. We were not able to find 
a relationship between the height of the serum levels of TPA and 
the best WHO response to treatment (data not shown). 
1. 
2. 
3. 
7. 
8. 
In conclusion, using strictly defined criteria for tumour 
marker response, Cyfra 2 1. I follows the changes in the tumour 
Souauet PI, Chauvin F. Boissel IP, et ul. Folvchemotherauv in 
advanced non small cell lung car&: ‘a meta-analysis. Lance2 i&3, 
342,19-21. 
Gaast A van der, Schoemnakers CHH, Kok TC, Blijenberg BG, 
Cornillie F, Splinter TAW. Evaluation of a new tumor marker in 
patients with non-small cell lung cancer: Cyfra 2 1.1. Br J Cancer 
1994,69,525-528. 
Hansson LO. Comparison of two assays (TPA and TPS) for 
cytokeratin polypeptides in serum using three different patient 
groups and in healthy subjects. In Rlapdor R, ed. Current Tumuur 
Diagnosis: Applications, Clinical Relevance, Research Trends. 
Munchen, W Zuckschwerdt, 1993,28. 
American Joint Committee on Cancer. In Beahrs OH, Henson 
DE, Hutter RV, Myers MH, eds. Manual for Staging of Cancer. 
Philadelphia, J.B. Lippincott, 1988,115-122. 
WHO. Handbook of Reporting Results of Cancer Treatment. Geneva, 
World Health Organization Offset publication No. 48,1979. 
Rastel D, Ramaioli A, Comillie F, Thirion B. Cyfra 2 1.1, a sensitive 
and specific new tumour marker for squamous cell hmg cancer. 
Report of the hrst European multicentre valuation. Eur 3 Cancer 
1994,30,601-606. 
Bates SE. Clinical applications of serum tumor markers. Intern Med 
1991,115,623-638. 
Bjorklund B, Bjorklund V. Biochemische und morphologische 
grundlagen von TPA. In Luthgens M, Schegel G, eds. Tumurmur- 
kersystem CEA-TPA. Leonberg, Tumor Diagnositik, 1987,14-30. 
load, which are still the basis for clinical decisions COnCeri’litlg Aclmow]edgement_Supported by a grant from Centmor D~mos&s, 
continuation of treatment, better than TPA. Rising levels of both Leuven, Belgium. 
